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The WHO End TB Strategy includes all the necessary 
elements to address the ongoing tuberculosis epi-
demic, while keeping an eye on the possibility of 
eliminating tuberculosis in both low-incidence 
and high-incidence settings.1,2 The global threat 
of multidrug-resistant tuberculosis is clearly 
acknowledged, with both national tuber culosis pro-
gram mes and individual clinicians facing severe 
challenges in managing this severe form of disease.3,4 
Clinicians often need to diagnose multidrug-resistant 
tuberculosis in disadvantaged populations. They 
must institute a regimen with a suﬃ  cient number of 
eﬀ ective drugs, and then support each patient’s ad-
herence through out a long and expensive treatment 
period during which toxic side-eﬀ ects frequently 
occur. Final out comes are largely suboptimal.1–6
Although new drugs (eg, bedaquiline and 
delamanid)7,8 and repurposed drugs (eg, linezolid, 
mero penem, and meﬂ oquine)9,10 are available and 
promising, more scientiﬁ c evidence is necessary 
to assess their potential impact on the epidemic of 
multidrug-resistant tuber culosis. They also need to be 
more easily available globally for suﬃ  cient controlled 
trials to be conducted.
Public health experts and policymakers need to 
organise a com plex management strategy, recom-
mending the cor rect diagnostic and treatment 
algorithms, while en suring—among other priorities—
economic sustain ability in resource-limited countries.5
Comprehensive surveillance of the prevalent drug-
resistance patterns of Mycobacterium tuberculosis at 
the regional and national level would be an extremely 
useful managerial tool to support clinicians and public 
health experts. Although substantial eﬀ orts have 
been made to describe the existing prevalence of drug 
resistance,1 estimations based on point-prevalence 
surveys might really help.
The study reported by Matteo Zignol and col-
leagues11 in The Lancet Infectious Diseases provides 
a multisite overview of population-based drug-
resistance patterns in countries with high incidence of 
drug-susceptible and multidrug-resistant tuberculosis. 
For the ﬁ rst time in the scientiﬁ c literature, the 
investigators provide important information about 
pyrazinamide and ﬂ uoroquinolone resistance. Their 
retrospective assessment, based on previous surveys 
of multidrug-resistant tuberculosis, included more 
than 5000 strains from Pakistan, South Africa, 
Azerbaijan, Bangladesh, and Belarus.
The prevalence of pyrazinamide and ﬂ uoroquinolone 
resistance varied in diﬀ erent settings. There was an 
association with rifampicin resistance, particularly 
when patients were previously exposed to anti-
tuberculosis therapy. No signiﬁ cant diﬀ erences in 
resistance pre valence were detected among the 
ﬂ uoroquinolones tested (oﬂ oxacin, levoﬂ oxacin, and 
moxiﬂ oxacin) within the countries surveyed. A core 
ﬁ nding was the highest cross resistance in oﬂ oxacin-
resistant mycobacterial strains for levoﬂ oxacin (>80%) 
and moxiﬂ oxacin when tested at 0·5 μg/mL (>70%).
Zignol and colleagues’ ﬁ ndings describing the 
pre valence of resistance to ﬂ uoroquinolones are 
original and extremely useful for both clinical and 
public health purposes; this study is timely and has 
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important implications. One such implication is that 
the prescription of pyrazinamide should be carefully 
evaluated in rifampicin-resistant cases. Rifampicin 
resistance can now be identiﬁ ed within just a few 
hours thanks to rapid molecular methods, and, if 
present, should lead to testing for resistance to 
pyrazinamide and ﬂ uoroquinolones. 
Although the overall prevalence of ﬂ uoroquinolone 
resistance in Zignol and colleagues’ study was low, the 
increased prevalence in some settings (eg, Pakistan 
and Bangladesh) raises concerns and questions the 
wisdom of empirical prescription of ﬂ uoroquinolones 
to patients with lower respiratory tract infections.
The reader might question whether the resistance 
patterns identiﬁ ed in this paper can be extrapolated 
to settings with a superﬁ cially similar tuberculosis 
epidemiology. A certain degree of caution is advisable 
in assuming that all countries with similar burdens of 
multidrug-resistant tuberculosis might have similar 
drug-resistance prevalence, because the statistical 
power in surveys of relatively rare events is low.
The new WHO-recommended regimen for 
multidrug-resistant tuberculosis (previously known 
as Bangladesh regimen), which is expected to 
increase patients’ adherence and programmatic 
sustainability (being shorter and cheaper), includes 
pyrazinamide and ﬂ uoro quinolones among its core 
drugs.12 The variability in drug resistance patterns 
calls for understanding of national and sub national 
epidemiology, and emphasises the need for rapid 
molecular methods and drug susceptibility testing to 
exclude drug resistance whenever there is suspicion 
that it might be present. Only with accurate and timely 
diagnosis will the spread of drug-resistant tuberculosis 
be contained. 
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A model of tuberculosis drug resistance highlights the 
burden in children
In the Lancet Infectious Diseases, Peter Dodd and 
colleagues1 report new estimates of the global burden 
of drug-resistant tuberculosis in children. This work 
builds on earlier estimates of paediatric tuberculosis 
in high-burden countries,2 WHO estimates of 
drug-resistant tuberculosis in children,3 and ﬁ ndings 
from two previous studies that produced global 
estimates.4,5
Improved estimates of the rates of drug resistance 
in children are important because paediatric tuber-
culosis can be more diﬃ  cult to diagnose, more chal-
lenging to test for drug sensitivity without access 
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